Voya Investment Management LLC Raises Holdings in BeOne Medicines Ltd. – Sponsored ADR $ONC

Voya Investment Management LLC boosted its stake in shares of BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) by 49.2% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 15,490 shares of the company’s stock after buying an additional 5,105 shares during the period. Voya Investment Management LLC’s holdings in BeOne Medicines were worth $5,277,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also bought and sold shares of the stock. Anchor Investment Management LLC bought a new position in shares of BeOne Medicines in the 2nd quarter worth $26,000. Caitong International Asset Management Co. Ltd purchased a new position in BeOne Medicines in the second quarter valued at about $28,000. Daiwa Securities Group Inc. bought a new position in BeOne Medicines in the second quarter worth about $35,000. Farther Finance Advisors LLC purchased a new stake in shares of BeOne Medicines during the second quarter valued at about $39,000. Finally, Signaturefd LLC bought a new stake in shares of BeOne Medicines in the 2nd quarter valued at about $49,000. Institutional investors own 48.55% of the company’s stock.

Analysts Set New Price Targets

Several research analysts recently commented on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of BeOne Medicines in a research note on Wednesday, October 8th. Citizens Jmp lifted their price target on shares of BeOne Medicines from $348.00 to $396.00 and gave the stock a “market outperform” rating in a report on Friday, November 7th. Royal Bank Of Canada reaffirmed an “outperform” rating on shares of BeOne Medicines in a research report on Wednesday, December 17th. Citigroup raised their price objective on BeOne Medicines from $399.00 to $405.00 and gave the stock a “buy” rating in a research report on Monday, November 10th. Finally, Barclays initiated coverage on BeOne Medicines in a research note on Thursday, September 18th. They set an “overweight” rating and a $385.00 target price on the stock. Twelve research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, BeOne Medicines presently has an average rating of “Moderate Buy” and a consensus target price of $365.79.

Insider Transactions at BeOne Medicines

In related news, COO Xiaobin Wu sold 3,991 shares of the company’s stock in a transaction that occurred on Monday, November 17th. The stock was sold at an average price of $380.43, for a total value of $1,518,296.13. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, Director Corazon (Corsee) D. Sanders sold 2,627 shares of the stock in a transaction that occurred on Wednesday, November 26th. The stock was sold at an average price of $340.90, for a total transaction of $895,544.30. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders sold 138,617 shares of company stock worth $44,632,898. 6.62% of the stock is owned by insiders.

BeOne Medicines Price Performance

Shares of ONC opened at $311.73 on Friday. The company has a debt-to-equity ratio of 0.03, a current ratio of 2.39 and a quick ratio of 2.17. The company’s fifty day moving average price is $327.41 and its 200-day moving average price is $308.97. BeOne Medicines Ltd. – Sponsored ADR has a 1-year low of $172.67 and a 1-year high of $385.22. The firm has a market capitalization of $36.95 billion, a PE ratio of 611.24 and a beta of 0.45.

BeOne Medicines Profile

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.